I've been impressed with how much mileage we are getting

New Post Public Reply Private Reply Replies (0) Message Board
sherlock57 My69z #164371
1,308
I've been impressed with how much mileage we are getting out of a single Phase 2 trial. 
[color=var(--text)]Not only seeing if Leronlimab works with the SOC in probably the biggest single cancer indication out there (numbers wise, with unmet needs). But comparing two relevant doses, with the opportunity to see dose-response at work. And an extension available to those who respond to the drug, and the rollover option for those who do not. And a primary endpoint--ORR--that is kind of low-hanging fruit.[/color]

[color=var(--text)]We also get to see if it reliably raises PDL-1 numbers. Which it apparently does... and we'll have the data to prove how much. [/color][color=var(--text)]In the rollover part of the trial we get to test the prime and pair hypothesis--prospectively--in up to 12 patients very sick patients in that indication. Without waiting around for a separate study...[/color]

And all throughout the trial we are capturing data on every biomarker imaginable that relates to leronlimab's effects on mCRC as well as CCR5 biology in the cancer context. They will be pouring over that data for years... (The academics will be all over it--think CCR5 classes at the University). And if they can come up with a predictive biomarker for efficacy (say ctDNA), then we are off to the races. And if we can pluck a biomarker associated with metastasis out of the Creatv or Natera data, it's game over! That, ultimately, is what I think they are after... once we get proof on the LL/ICI combo.

How did Dr J and the team get all this blessed by the FDA? No doubt having Dr Kasi on board was a part of this, and the early ctDNA declines are convincing. (Lalezari's comment about the data doing the talking now certainly applies here). But it all seems clear that the FDA has come around and is more receptive to "adoptive" trial design these days. So the timing on this for Cytodyn is great... But no doubt Dr J called in any and every favor anyone might have owed him to make this happen. And he is a pretty sharp cat, and a persuasive one at that. 

My69's point that doing a dedicated trial with an ICI first "would simply confound Cytodyn's data" is accurate. Although in one interview Dr J did suggest he expected to trial the combo, or essentially go straight to an ICI if a patient progressed during the trial. Perhaps the negotiations that led to the Clover protocol will be discussed at some future point, and we'll see what exactly happened. Maybe the FDA actually leaned on Cytodyn a bit, and Lalezari went  along? All I can say is all's well that ends well.

Now, Ken Chowder and Misiu might very well be quick to say that it didn't end well for those who passed. That is true. But there is no certainty that as 3rd-line mCRC patients--quite sick--the leronlimab/ICI combo would have saved their lives. Just assuming so carries the implication that we can extrapolate the 5 out of 5 TNBC survivors to another deadly cancer, with a different biology, and a larger patient pool. I do not know the ages of the Ladies of Leronlimab; but age and health status may very well have played a part in their survival. We do not know. And part of the Clover trial is to find out what Leronlimab can and can't do.

And please, do not forget human agency in all this. Both the choice to enter the trial in the first place, and to stay with it as the trial proceeds. There are other investigational drug trials available for 3rd-line mCRC patients. And right-to-try options. If I was part of the Clover trial and progressed but managed to get my PDL-1 numbers up, I would jump ship right away. And by that I mean not wait around for the rollover, and get an ICI somewhere, somehow, some way! That might very well have already happened. Anyway, criticizing Dr J and Cytodyn for basically taking direction from the FDA, and learning all we can about the ultimate relevance of LL as part of a new standard of care in mCRC, under the assumption that LL and an ICI is going to save EVERYONE... or perhaps even the majority of these sick patients... That is likely misplaced.

Finally, completing Clover-as-designed will provide plenty of vital information to guide oncologists in their use of Leronlimab as part of a new SOC in the very near future. How many lives will that save? That is the great cosmic question I haven't heard posed by anyone here or on Livimmune. For the religious, isn't that a question for the man upstairs with the Big Ledger? Down here, go ahead and calculate it out, if you like. It is not my place. Look, I feel uncomfortable talking about life and death like this... Exposed. But these things need to be talked about openly, with all respect and prayers for lives lost. And urgency for lives to save. 

Yes, patients are going to die in this trial. Clover seems to offer them a remarkable amount of options and agency as they proceed on their journey, and face their destiny. I don't know a trial that has offered as much. 

  

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 89

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 110

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 77

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 112

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Feeding America Urges Collaboration to Combat Hunger Crisis

Updated Category News Views 148

Feeding America's Call to Action Against Hunger As food insecurity continues to rise, people across the nation who are struggling with hunger are urging us to unite and take meaningful steps to tackle this critical issue. Recent data indicates a troubling 6% increase in food insecurity over the past year, highlighting the immediate need for a collective response. Even...

Continue Reading
Aviat Networks Announces Participation in Key Investor Events

Updated Category News Views 136

Exciting Investor Conferences Ahead for Aviat Networks Aviat Networks, Inc. (NASDAQ: AVNW), a prominent player in the realm of wireless transport and access solutions, has recently unveiled its participation in some significant upcoming investor conferences. These conferences are an excellent opportunity for investors to engage with the company and learn more about its...

Continue Reading
Berkshire Hathaway Secures $1.9B with Major Samurai Bond Sale

Updated Category News Views 277

Berkshire Hathaway's Significant Samurai Bond Offering Berkshire Hathaway (NYSE: BRK) has successfully concluded a major bond offering, securing 281.8 billion yen, which is approximately $1.9 billion. This achievement marks the company's largest Samurai bond sale in five years, reflecting its strategic intent to deepen its investment footprint in the Japanese market. The...

Continue Reading
Top 10 Trading Mistakes to Avoid for Successful Investing

Updated Category News Views 150

The Costly Errors in Trading Many traders stumble not due to a lack of opportunities, but because they inadvertently make damaging decisions. It's crucial to recognize that the line between success and failure often lies in avoiding habits that negatively impact your trading account. In this article, we will delve into the 10 most detrimental trading mistakes....

Continue Reading
DEWALT POWERSHIFT™: Revolutionizing Electric Tools for Future Jobsites

Updated Category News Views 344

DEWALT POWERSHIFT™: A Leap Towards Sustainability DEWALT, a distinguished name in construction tools, has just introduced the DEWALT POWERSHIFT™ Cordless Equipment System, a groundbreaking series of tools designed to transform the future of jobsites. This innovative system significantly reduces environmental impact, boasting a remarkable capability to produce up to...

Continue Reading